Abstract: The subject invention pertains to new thermostable enzymes and the use of these enzymes both in proteolysis as well as protein and polypeptide synthesis. The subject invention further concerns polynucleotide sequences which encode the enzymes of the subject invention.
Type:
Grant
Filed:
April 15, 2004
Date of Patent:
March 20, 2007
Assignee:
University of Florida Research Foundation, Inc.
Abstract: A peptide corresponding to positions 62–71 of the sequence of human C-reactive protein (CRP) of the formula: Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71 and modifications thereof obtained by substitution, deletion, or addition of amino acids, amidation of the C-terminal or acylation of the N-terminal, are capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG) and can be used for the treatment of chronic inflammation conditions such as rheumatoid arthritis, pulmonary emphysema, cystic fibrosis, bronchitis, asthma and some acute respiratory distress syndrome.
Abstract: The present invention relates to thermostable proteases having an amino acid sequence which homologous to the amino acid sequence of proteases derived from Nocardiopsis, and the production thereof by wild-type and recombinant host cells including transgenic plants and non-human transgenic animals. The proteases are effective in animal feed, in particular fish feed, and detergents. The proteases are capable of degrading the soybean Bowman-Birk inhibitor, and other antinutritional factors such as soybean agglutinin and the Kunitz trypsin inhibitor, as well as the isolated soy storage proteins glycinin and beta-conglycinin. Characteristic structural features of relevance for the thermostability of these proteases of peptidase family S2A or S1E are disclosed.
Abstract: The present invention relates to a novel carboxypeptidase gene and the polypeptide encoded thereby. In particular, the present invention relates to the use of the present carboxypeptidase and polypeptide in the manufacture of cocoa flavor and/or chocolate.
Type:
Grant
Filed:
March 5, 2003
Date of Patent:
February 13, 2007
Assignee:
Nestec S.A.
Inventors:
Maryse Laloi, James McCarthy, Peter Bucheli
Abstract: The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utflized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other maninials, and kits which may be used for the detection of diseases and disorders.
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
January 30, 2007
Assignee:
The Trustees of Boston University
Inventors:
Kenneth J. Rothschild, Sanjay M. Sonar, Jerzy Olejnik
Abstract: The present invention relates to conjugates of a lipid, substrate peptide of an enzyme secreted from the cells of mammals, including humans, and a water-soluble polymer that can be used as colloidal carriers and the like of tissue-specific drug delivery systems, methods of producing these conjugates, peptide-water-soluble polymer conjugates optionally having protective groups that are useful as the intermediates of these conjugates, colloidal carriers made from these conjugates, and tissue-specific drug delivery systems that use these colloidal carriers.
Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. Polypeptides used herein are derived from human BACE which is also known by the synonyms “mamapsin 2”, “human ?-site APP-cleaving enzyme, and Asp2”. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.
Type:
Grant
Filed:
May 22, 2003
Date of Patent:
January 23, 2007
Assignee:
Schering Corporation
Inventors:
Brian M. Beyer, Bruce A. Malcolm, Corey O. Strickland, Wenyan Wang, Eileen Wilson
Abstract: The invention disclosed herein provides clot specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.
Abstract: Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.
Type:
Grant
Filed:
November 5, 2004
Date of Patent:
January 2, 2007
Assignee:
Ferring BV
Inventors:
Steve Qi, Karen O. Akinsanya, Pierre J-M Riviere, Jean-Louis Junien
Abstract: A method is described for treating biological cells and/or their cell components with electrical fields in a reaction medium, in which an inhibitor is added to the reaction medium to counteract the action of enzymes that break down protein.
Abstract: A hyperthermostable protease having the amino acid sequence represented by the SEQ ID NO:1 of the Sequence Listing or a sequence derived therefrom by deletion, substitution, insertion or addition of one to several amino acid residues, a gene encoding the hyperthermostable protease, and a process for preparing the protease, aiming at providing by genetic engineering techniques a hyperthermophile protease which is advantageous for industrial use.
Abstract: Test system for the determination of in-vivo active hemostasis proteases or of trypsin or subtilisin in biological fluids and the usage thereof to determine the in-vivo activation of hemostasis or to diagnose pancreatitis.
Abstract: The invention provides, in part, compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also provides, in part, nucleic acid molecules encoding such polypeptides, and methods of making such polypeptides and nucleic acid molecules.
Type:
Grant
Filed:
August 25, 2000
Date of Patent:
November 7, 2006
Assignee:
Allergan, Inc.
Inventors:
J. Oliver Dolly, Yan Li, Kuo Chion Chan
Abstract: Novel aggrecanase proteins and the nucleotide sequences encoding them as well as processes for producing them are disclosed. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
Abstract: Provided is a kit that composes of two products and its method of use to promote hair growth. The kit has two products that are applied to the scalp of a human sequentially. The first product applied to the scalp of a human is a monoethanolamine salt composition that is combined with an organic enzyme. The second product is an oxidizing agent.
Abstract: DNA molecules comprising a sequence encoding the signal peptide of hGH linked to a heterologous protein and related cells, methods and fusion proteins.
Type:
Grant
Filed:
December 12, 2002
Date of Patent:
October 17, 2006
Assignee:
Transkaryotic Therapies, Inc.
Inventors:
Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
Abstract: The present invention discloses methods for activating Caspase 9 in such a way that it can be used in assays to discover modulators of Caspase 9.
Abstract: The present invention is a substantially purified sortase-transamidase enzyme from Gram-positive bacteria, such as Staphylococcus aureus. A specific sortase-transamidase enzyme disclosed has a molecular weight of about 29,076 daltons and catalyzes a reaction that covalently cross-links the carboxyl terminus of a protein having a sorting signal to the peptidoglycan of a Gram-positive bacterium, where the sorting signal has a a motif of NPQ/KTN/G therein. Variants of the enzyme, methods for cloning the gene encoding the enzyme and expressing the cloned gene, and methods of use of the enzyme, including for screening for antibiotics and for display of proteins or peptides on the surfaces of Gram-positive bacteria, are also disclosed.
Type:
Grant
Filed:
August 14, 2002
Date of Patent:
September 5, 2006
Assignee:
The Regents of the University of California
Inventors:
Olaf Schneewind, Sarkis K. Mazmanian, Gwen Liu, Hong Ton-That
Abstract: The present invention relates to isolated polypeptides having dipeptidyl aminopeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
November 25, 2003
Date of Patent:
August 29, 2006
Assignee:
Novozymes, Inc.
Inventors:
Alexandeer Blinkovsky, Kimberly Brown, Michael W. Rey, Alan Klotz, Tony Byun
Abstract: The invention provides isolated nucleic acids molecules, designated 53010 nucleic acid molecules, which encode novel carboxylesterase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53010 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53010 gene has been introduced or disrupted. The invention still further provides isolated 53010 proteins, fusion proteins, antigenic peptides and anti-53010 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Type:
Grant
Filed:
September 29, 2003
Date of Patent:
August 22, 2006
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Rory A. J. Curtis, Inmaculada Silos-Santiago
Abstract: The present invention relates to polypeptides having carboxypeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to methods of obtaining protein hydrolysates useful as flavor improving agents.
Type:
Grant
Filed:
March 4, 2005
Date of Patent:
August 15, 2006
Assignees:
Novozymes, Inc., Novozymes A/S
Inventors:
Alexander Blinkovsky, Randy Berka, Michael Rey, Elizabeth Golightly, Alan Klotz, Thomas Erik Mathisen, Claus Dambmann
Abstract: Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are administered through a topical delivery medium for absorption into a dermis of the individual.
Abstract: The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of Clostridium histolyticum. It is provided for that the enzymes of the excess fermentation are separated by a multistage chromatography method by exclusively using chromatography materials on styrene/divinyl-benzene base and/or on base of in particular ceramic hydroxylapatite.
Abstract: Provided are compositions comprising monoethanolamine salts of thioglycolic, salicylic, lactic and glycolic acids in combination with an organic enzyme, preferably papain, and an oxidizing aged their methods of use to induce hair growth in the scalp of humans and other mammals.
Abstract: The present invention describes isolated polypeptides from fungi which have aminopeptidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
August 22, 2001
Date of Patent:
July 18, 2006
Assignee:
DSM IP Assets B.V.
Inventors:
Danielle Basten, Petrus Jacobus Theodorus Dekker, Paul William Schuurhuizen, Jacob Visser, Petrus Johannes Schaap
Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
Abstract: The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.
Type:
Grant
Filed:
February 24, 2003
Date of Patent:
July 4, 2006
Assignees:
ARCH Development Corporation, Dana Farber Cancer Institute
Abstract: In this paper, we describe RT-PCR strategies that allowed us to identify and clone members of the NEP-like family. Degenerate oligoncleotide primers corresponding to consensus sequences located on either side of the HEXXH consensus sequence for zincins were designed and used in RT-PCR with mouse and human testis cDNAs. DNA fragments with lengths expected from the sequence of this class of enzympes were obtained. These DNA fragments were cloned and sequenced. Using this PCR strategy and the PCR fragments as probes to screen cDNA libraries, three zincin-like peptidases were identified in addition of known members of the family. The cDNA sequences allowed to derive specific probes for Northern and in situ hybridization, and probe human chromosomes to localize the gene and establish potential links to genetic diseases. Furthermore, these cDNA sequences were used to produce recombinant fusion proteins in Escherichia coli in order to raise specific antibodies.
Abstract: A novel carboxypeptidase and the encoding gene thereof were successfully identified by screening a human hippocampus extract using brain-APP-cleaving activity as an index. This protein and its gene are useful in, for example, preventing, treating, examining, and diagnosing Alzheimer's disease, and such.
Abstract: The present invention concerns fluorescent proteins modified such that said modified fluorescent protein incorporates a cleavage site for a protease, cleavage of said modified fluorescent protein at said cleavage site by said protease causing the alteration of at least one of the emission and excitation spectra of said modified fluorescent protein. In particular, the invention is concerned with using these modified fluorescent proteins as probes for detecting protease activity in living cells during the programmed cell death process (apoptosis). Also provided are nucleic acid sequence encoding same, recombinant DNA constructs expressing same, cells transformed or transfected with same, methods for detecting protease activity, and methods of detecting agents which affect protease activity, and kits for same.
Type:
Grant
Filed:
April 18, 2000
Date of Patent:
May 23, 2006
Assignee:
The Hong Kong University of Science and Technology
Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.
Type:
Grant
Filed:
October 21, 2002
Date of Patent:
May 2, 2006
Assignee:
Applera Corporation
Inventors:
Weiniu Gan, Jane Ye, Valentina Di Francesco, Ellen M. Beasley
Abstract: The present invention relates to a method of assaying modulators of the interaction between Wolframin protein and its identified cellular binding partner.
Abstract: The present invention provides novel polynucleotides encoding MMP-29 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MMP-29 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
Abstract: The present invention relates to determining the prethrombotic state, in particular determining an amount or presence of circulating microparticles and/or stimulated procoagulant cells.
Type:
Grant
Filed:
June 7, 2000
Date of Patent:
February 28, 2006
Inventors:
Jean-Marie Freyssinet, Benedicte Antoni, Frederic Donie, Helmut Lill
Abstract: An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.
Type:
Grant
Filed:
June 6, 2002
Date of Patent:
February 28, 2006
Assignee:
The Regents of the University of California
Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).
Type:
Grant
Filed:
September 7, 2001
Date of Patent:
January 31, 2006
Assignee:
Pfizer Inc.
Inventors:
Neil Benson, Helen Frances Boyd, Leonard Gabriel Contillo, Ian Dennis Harrow, Stephen Charles Phillips, David Harlan Singleton, Peter Stacey, Roderick Thomas Walsh, Christopher Peter Wayman
Abstract: Thermostable peptidase enzyme derived from archaeon from the genus Pyrococcus is disclosed. The enzyme is produced from native or recombinant host cells and can be utilized in the biotechnology industry as a useful enzyme in sequencing reactions.
Type:
Grant
Filed:
September 24, 2001
Date of Patent:
November 22, 2005
Assignee:
California Institute of Technology
Inventors:
Timothy C. Cheng, Vij Ramakrishnan, Sunney I. Chan
Abstract: Methionine aminopeptidases catalyse the co-translational removal of amino terminal methionine residues from nascent polypeptide chains. A newly-discovered enzyme, designated methionine aminopeptidase type-3 (MetAP-3), has a substrate specificity which is similar to MetAP-1 and MetAP-2, although it is not inhibited by fumagillin, an irreversible inhibitor of MetAP-2. MetAP-3 also preferentially localizes to mitochondria, unlike MetAP-1 and MetAP-2, which accumulate in the cytoplasm. One embodiment of the present invention relates to human cDNAs encoding polypeptides comprising MetAP-3. Other embodiments of the invention relate to nucleic acid molecules derived from these cDNAs, including complements, homologues, and fragments thereof, and methods of using these nucleic acid molecules, to generate polypeptides and fragments thereof.
Type:
Grant
Filed:
November 19, 2002
Date of Patent:
October 11, 2005
Assignee:
Pharmacia Corporation
Inventors:
Carolyn J. Sympson, Rajeev Aurora, Stanton B. Dotson, Ronald B. Frazier, Cynthia L. Woods, Hamideh Zakeri, Xianzhi Zhou
Abstract: The present invention relates to polypeptides having carboxypeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides. The present invention further relates to methods of obtaining protein hydrolysates useful as flavor improving agents.
Type:
Grant
Filed:
November 13, 2000
Date of Patent:
October 4, 2005
Assignees:
Novozymes Biotech, Inc., Novozymes A/S
Inventors:
Alexander Blinkovsky, Randy Berka, Michael Rey, Elizabeth Golightly, Alan Klotz, Thomas Erik Mathisen, Claus Dambmann
Abstract: The present invention relates to methods of producing a polypeptide comprising culturing a mutant of a parent cell, wherein the mutant produces less oxaloacetate hydrolase than the parent cell, wherein the oxaloacetate hydrolase (i) has an amino acid sequence that has at least 90% identity with amino acids 1-341 of SEQ ID NO: 2: (ii) is encoded by a nucleic acid sequence having at least 90% homology with a nucleotide sequence comprising nuclotides 1157-1411, 1504-1651 and 1764-2383 of SEQ ID NO: 1: (iii) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with the nucleic acid sequence of SEQ ID NO: 1, the cDNA sequence of SEQ ID NO: 1, the complementary strand of SEQ ID NO: 1, and/or the complementary strand of the cDNA sequence of SEQ ID NO: 1: and/or (iv) a subsequence of one or both of (i) and (ii), wherein the subsequence encodes a fragment that has oxaloacetate hydrolase activity.
Abstract: The present invention relates to a process for the recombinant production of a desired heterologous polypeptide with a clearly defined homogenous N-terminus in a bacteria host cell. A fusion comprising a peptide with the autoproteolytic activity of an autoprotease Npro of a pestivirus and the heterologous polypeptide is initially expressed in the form of cytoplasmic inclusion bodies in the host cell, the inclusion bodies are isolated and subsequently treated so that the desired heterologous polypeptide is cleaved autoproteolytically by the Npro activity of the fusion protein.
Type:
Grant
Filed:
August 7, 2000
Date of Patent:
August 30, 2005
Assignee:
Sandoz AG
Inventors:
Günter Stempfer, Jörg Windisch, Franz Knauseder
Abstract: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application to teeth whereby enzyme activity is maintained with improved dentifrice foaming characteristics.
Type:
Grant
Filed:
August 28, 2002
Date of Patent:
August 9, 2005
Assignee:
Colgate-Palmolive Company
Inventors:
Malcolm Williams, Michael Prencipe, James G. Masters
Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.
Type:
Grant
Filed:
February 1, 2002
Date of Patent:
August 9, 2005
Assignee:
Applera Corporation
Inventors:
Marion Webster, Karen A. Ketchum, Valentina Di Francesco, Ellen M. Beasley
Abstract: A novel proteinase inhibitor and materials and methods for making it are disclosed. The proteinase inhibitor comprises residues 3-425 of SEQ ID NO:2. The proteinase inhibitor may be used as components of cell culture media, in protein purification, and in certain therapeutic and diagnostic applications.
Abstract: A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.
Abstract: The present invention relates to the identification of novel serine proteases in Gram-positive microorganisms. The present invention provides the nucleic acid and amino acid sequences for the Bacillus subtilis serine proteases SP1, SP2, SP3, SP4 and SP5. The present invention also provides host cells having a mutation or deletion of part or all of the gene encoding SP1, SP2, SP3, SP4 and SP5. The present invention also provides host cells further comprising nucleic acid encoding desired heterologous proteins such as enzymes. The present invention also provides a cleaning composition comprising a serine protease of the present invention.
Abstract: There are provided proteins having the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8 and 10; proteins having amino acid sequences derived from these amino acid sequences by deletion, substitution or addition of one to several amino acids; and nucleotide sequences encoding the same; transgenic non-human animals with altered expression level of a serine protease BSSP2; an antibody against BSSP2; and a method for detecting BSSP2 in a specimen by using the antibody.
Abstract: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
Abstract: The present invention relates to a novel methods and compositions for producing hyper and hypo allergenic compositions. Specifically, the present invention comprises neutralizing or reducing the ability of T-cells to recognize epitopes and thus prevent sensitization of an individual to the protein. Alternatively, T-cell epitopes are mutated to produce increased immunogenic reactions.